Developer of a novel, safe treatment for Scleroderma
JB Therapeutics is developing breakthrough medicines that are based on the medicinal properties of cannabis, using pure active ingredients that produce none of the negative, psychotropic side effects commonly associated with the plant. By removing this controversial stigma through synthetic chemical redesign, its lead compound, JBT-101, is now poised to become a leading treatment for scleroderma, a debilitating disease with no known cure and inadequate therapies. Current treatments for scleroderma are fraught with intolerable side effects and poor results. Essentially, the patient is forced to choose between treatment and quality of life. JBT-101 acts on natural pathways in the body to resolve pain, inflammation and fibrosis, all of which are symptoms of scleroderma.